Contract wins for life sciences business as it scales up operations
York-based life sciences firm, Aptamer Group, has hailed growing commercial momentum as it publishes its interim results for the six months ended 31 December 2022.
The York-headquartered business, which develops Optimer ® binders that can be used as synthetic alternatives to antibodies, reports revenues of £1m (H1 2022: £1.4m, FY 2022: £4m), with additional £1m worth of signed orders at 31 December 2022 and further contracts signed post-period end.
The company made a pre-tax loss of £3m (H1 2022: £1.2m loss) and an adjusted EBITDA loss of £2.5m (H1 2022: £0.6m, FY 2022: £1.7m).
Dr Arron Tolley, chief executive officer, said: “The first half of the year has seen Aptamer sign contracts across all business units, including with several top 10 pharmaceutical companies, and strong contract signing post-period.
“During the first half, we significantly scaled our operations and expanded our development capacity, underpinned by our move to custom-fitted premises.
“Looking ahead, we anticipate significantly higher revenues in the second half with a material uplift occurring in the final quarter of our financial year, as many of the current contracted development projects near completion or begin secondary phases.
“In addition, we have a strong and growing pipeline of qualified opportunities reflecting the increasing global demand for our services and recognition across the life sciences market of the technology’s capabilities and value.”
Aptamer completed a planned relocation to larger, purpose-built laboratories in November, supporting its work to scale up its operations, streamline workflows and service increased demand for Optimer binders.
